GJB2_HUMAN,L205V,0.756,, ELME000070|ELME000333,-
GJB2_HUMAN,L205F,0.821,, ELME000070|ELME000333,-
GJB2_HUMAN,L132V,0.779,Loss of Helix (Pr = 0.33 | P = 1.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Strand (Pr = 0.29 | P = 6.1e-03); Altered DNA binding (Pr = 0.27 | P = 6.0e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.08 | P = 0.04); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,A40G,0.665,Loss of Helix (Pr = 0.33 | P = 1.2e-03); Gain of Strand (Pr = 0.30 | P = 3.1e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), None,-
GJB2_HUMAN,A40E,0.879,Altered Metal binding (Pr = 0.42 | P = 7.6e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 9.4e-04); Loss of Strand (Pr = 0.26 | P = 0.05), None,-
GJB2_HUMAN,A40V,0.741,Loss of Helix (Pr = 0.29 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04); Gain of Strand (Pr = 0.26 | P = 0.04), None,-
GJB2_HUMAN,N14Y,0.866,Altered Ordered interface (Pr = 0.37 | P = 5.5e-04); Gain of Strand (Pr = 0.27 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03), None,-
GJB2_HUMAN,N14K,0.819,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000008|PS00004,-
GJB2_HUMAN,T8M,0.095,-,-,-
GJB2_HUMAN,T8K,0.227,-,-,-
GJB2_HUMAN,T8S,0.065,-,-,-
GJB2_HUMAN,V63L,0.845,Altered Metal binding (Pr = 0.30 | P = 4.2e-03); Altered Ordered interface (Pr = 0.27 | P = 9.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02), ELME000079|ELME000106|PS00407,-
GJB2_HUMAN,S72C,0.882,Altered Metal binding (Pr = 0.42 | P = 7.6e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Altered Ordered interface (Pr = 0.32 | P = 0.01), None,-
GJB2_HUMAN,D50A,0.807,Altered Transmembrane protein (Pr = 0.32 | P = 6.3e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.8e-03); Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 2.5e-03); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.15 | P = 4.7e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,D50N,0.680,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.25 | P = 7.0e-03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.3e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,D50Y,0.878,Altered Transmembrane protein (Pr = 0.34 | P = 4.9e-05); Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.4e-03); Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Disulfide linkage at C53 (Pr = 0.28 | P = 2.0e-03); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.14 | P = 5.0e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04); Gain of Sulfation at D50 (Pr = 0.02 | P = 0.03), ELME000182,-
GJB2_HUMAN,I140S,0.829,Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at Y136 (Pr = 0.09 | P = 0.05), ELME000052|ELME000197|ELME000337,-
GJB2_HUMAN,G12V,0.798,Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000335,-
GJB2_HUMAN,G12D,0.807,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Gain of Relative solvent accessibility (Pr = 0.31 | P = 5.3e-03), None,-
GJB2_HUMAN,G12R,0.767,Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), None,-
GJB2_HUMAN,G12C,0.827,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.2e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03), None,-
GJB2_HUMAN,I128M,0.486,-,-,-
GJB2_HUMAN,I128V,0.286,-,-,-
GJB2_HUMAN,N206T,0.725,, ELME000064|ELME000070|ELME000220|ELME000333|PS00001|PS00006,-
GJB2_HUMAN,N206S,0.601,, ELME000064|ELME000070|ELME000333|PS00001|PS00006,-
GJB2_HUMAN,N206H,0.682,, ELME000070|ELME000333|PS00001,-
GJB2_HUMAN,K112N,0.204,-,-,-
GJB2_HUMAN,H73Y,0.855,Altered Metal binding (Pr = 0.38 | P = 1.6e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.1e-03), ELME000020|ELME000083|ELME000120|ELME000182,-
GJB2_HUMAN,H73R,0.880,Altered Metal binding (Pr = 0.38 | P = 1.7e-03); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03), ELME000012|ELME000231|ELME000233,-
GJB2_HUMAN,G11E,0.666,Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000064|ELME000220|PS00006,-
GJB2_HUMAN,M163V,0.726,Altered Transmembrane protein (Pr = 0.30 | P = 2.1e-04); Altered Ordered interface (Pr = 0.29 | P = 5.6e-03); Gain of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000148,-
GJB2_HUMAN,M163L,0.685,Altered Ordered interface (Pr = 0.29 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000148,-
GJB2_HUMAN,L90P,0.934,Gain of Allosteric site at H94 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052,-
GJB2_HUMAN,L90R,0.910,Gain of Allosteric site at H94 (Pr = 0.24 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052|ELME000313,-
GJB2_HUMAN,L90V,0.628,Loss of Allosteric site at H94 (Pr = 0.21 | P = 0.04); Altered Coiled coil (Pr = 0.12 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052,-
GJB2_HUMAN,A88G,0.403,-,-,-
GJB2_HUMAN,A88V,0.448,-,-,-
GJB2_HUMAN,A88S,0.287,-,-,-
GJB2_HUMAN,A88P,0.775,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Coiled coil (Pr = 0.11 | P = 0.04), ELME000052|ELME000136|ELME000159|ELME000358,-
GJB2_HUMAN,V226D,0.766,Altered DNA binding (Pr = 0.41 | P = 2.9e-04); Gain of B-factor (Pr = 0.37 | P = 5.8e-05); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.29 | P = 0.03), ELME000011,-
GJB2_HUMAN,V226G,0.646,Gain of B-factor (Pr = 0.36 | P = 1.3e-04); Altered DNA binding (Pr = 0.36 | P = 7.4e-04); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 0.04), ELME000011,-
GJB2_HUMAN,V226A,0.353,-,-,-
GJB2_HUMAN,M34I,0.784,Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.18 | P = 8.9e-03), ELME000148|ELME000149,-
GJB2_HUMAN,M34V,0.826,Loss of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03), ELME000148|ELME000149,-
GJB2_HUMAN,M34R,0.916,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Gain of Catalytic site at R32 (Pr = 0.09 | P = 0.04), ELME000012|ELME000106|ELME000148|ELME000149,-
GJB2_HUMAN,M34T,0.860,Loss of Helix (Pr = 0.30 | P = 7.9e-03); Gain of Strand (Pr = 0.28 | P = 8.4e-03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03), ELME000052|ELME000062|ELME000148|ELME000149|ELME000335|ELME000336,-
GJB2_HUMAN,M34L,0.729,Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.28 | P = 5.9e-03); Altered Transmembrane protein (Pr = 0.18 | P = 8.3e-03), ELME000106|ELME000148|ELME000149,-
GJB2_HUMAN,T186M,0.858,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Loss of Allosteric site at R184 (Pr = 0.21 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000147|ELME000336|PS00005,-
GJB2_HUMAN,T186K,0.932,Altered Transmembrane protein (Pr = 0.32 | P = 1.1e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.26 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at R184 (Pr = 0.23 | P = 0.02); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Methylation at K188 (Pr = 0.09 | P = 0.05), ELME000062|ELME000063|ELME000147|PS00005,-
GJB2_HUMAN,C202F,0.910,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000197,-
GJB2_HUMAN,C202R,0.907,, ELME000106|ELME000146,-
GJB2_HUMAN,S139N,0.755,Gain of Helix (Pr = 0.30 | P = 9.2e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000052|ELME000182|ELME000197|ELME000337,-
GJB2_HUMAN,S139C,0.790,Altered Ordered interface (Pr = 0.34 | P = 6.0e-03); Gain of Helix (Pr = 0.30 | P = 8.2e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000052|ELME000182|ELME000197|ELME000337,-
GJB2_HUMAN,C64Y,0.952,Altered Metal binding (Pr = 0.66 | P = 1.3e-03); Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C64 (Pr = 0.21 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02), ELME000079|PS00407,-
GJB2_HUMAN,I71N,0.894,Altered Metal binding (Pr = 0.31 | P = 4.6e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 2.2e-04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Allosteric site at R75 (Pr = 0.18 | P = 0.05), ELME000120|ELME000182,-
GJB2_HUMAN,I71V,0.221,-,-,-
GJB2_HUMAN,N176D,0.796,Altered Transmembrane protein (Pr = 0.27 | P = 7.9e-04); Loss of Disulfide linkage at C174 (Pr = 0.25 | P = 6.1e-03); Altered Metal binding (Pr = 0.24 | P = 0.03); Gain of Catalytic site at C180 (Pr = 0.08 | P = 0.05), PS00408,-
GJB2_HUMAN,N176T,0.847,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Loss of Disulfide linkage at C174 (Pr = 0.26 | P = 4.2e-03), ELME000220|PS00006|PS00408,-
GJB2_HUMAN,E114K,0.247,-,-,-
GJB2_HUMAN,E114G,0.285,-,-,-
GJB2_HUMAN,S113R,0.127,-,-,-
GJB2_HUMAN,S113N,0.049,-,-,-
GJB2_HUMAN,S113T,0.064,-,-,-
GJB2_HUMAN,M93T,0.798,Altered Ordered interface (Pr = 0.24 | P = 0.04); Gain of Allosteric site at H94 (Pr = 0.22 | P = 0.02); Altered Stability (Pr = 0.14 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000336,-
GJB2_HUMAN,L89P,0.905,Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Allosteric site at H94 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.12 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05); Altered Metal binding (Pr = 0.08 | P = 0.02), ELME000052|ELME000141|ELME000159|ELME000358,-
GJB2_HUMAN,S183F,0.926,Altered Ordered interface (Pr = 0.33 | P = 8.7e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Allosteric site at R184 (Pr = 0.22 | P = 0.03); Loss of Disulfide linkage at C180 (Pr = 0.14 | P = 0.04), ELME000062|ELME000063|ELME000155|PS00408,-
GJB2_HUMAN,C218Y,0.479,-,-,-
GJB2_HUMAN,I30N,0.945,Altered Transmembrane protein (Pr = 0.24 | P = 2.1e-03); Gain of Catalytic site at R32 (Pr = 0.08 | P = 0.05), ELME000148|ELME000335,-
GJB2_HUMAN,I30V,0.628,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000335,-
GJB2_HUMAN,R143Q,0.717,Gain of Strand (Pr = 0.28 | P = 7.4e-03), ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,R143L,0.865,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000041|ELME000047|ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,R143W,0.851,Gain of Strand (Pr = 0.28 | P = 0.01), ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,T55A,0.848,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 0.01); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), PS00407,-
GJB2_HUMAN,T55P,0.931,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 8.5e-03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 7.4e-03), ELME000155|PS00407,-
GJB2_HUMAN,T55N,0.879,Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.6e-03); Altered Metal binding (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Disulfide linkage at C53 (Pr = 0.28 | P = 1.4e-03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.7e-03), PS00407,-
GJB2_HUMAN,L56P,0.884,Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 8.7e-03); Gain of Catalytic site at C60 (Pr = 0.18 | P = 0.02); Altered Stability (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), ELME000136|ELME000159|PS00407,-
GJB2_HUMAN,L56Q,0.692,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.25 | P = 6.6e-03); Gain of Catalytic site at C60 (Pr = 0.20 | P = 0.01); Gain of Pyrrolidone carboxylic acid at L56 (Pr = 0.14 | P = 5.3e-03), ELME000202|PS00407,-
GJB2_HUMAN,A197S,0.187,-,-,-
GJB2_HUMAN,A197V,0.379,-,-,-
GJB2_HUMAN,K61Q,0.550,Gain of Catalytic site at C60 (Pr = 0.31 | P = 1.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Altered Metal binding (Pr = 0.29 | P = 4.8e-03); Altered Ordered interface (Pr = 0.27 | P = 7.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Loss of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.13 | P = 6.7e-03), PS00407,-
GJB2_HUMAN,R98Q,0.181,-,-,-
GJB2_HUMAN,R98W,0.317,-,-,-
GJB2_HUMAN,R98P,0.568,Loss of Helix (Pr = 0.33 | P = 1.6e-03); Gain of Allosteric site at H94 (Pr = 0.24 | P = 0.01); Altered Disordered interface (Pr = 0.20 | P = 0.04); Altered Coiled coil (Pr = 0.14 | P = 0.03); Altered Metal binding (Pr = 0.08 | P = 0.01), ELME000012|ELME000102|ELME000108|ELME000155,-
GJB2_HUMAN,R98H,0.184,-,-,-
GJB2_HUMAN,R98Y,0.377,-,-,-
GJB2_HUMAN,S85P,0.858,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,S85T,0.458,-,-,-
GJB2_HUMAN,T86R,0.748,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000136|ELME000146|ELME000149|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,T86A,0.502,Loss of Strand (Pr = 0.30 | P = 2.5e-03); Altered Coiled coil (Pr = 0.13 | P = 0.03), ELME000041|ELME000052|ELME000085|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,K22N,0.693,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 7.3e-03); Gain of Catalytic site at K22 (Pr = 0.15 | P = 0.02), None,-
GJB2_HUMAN,P58R,0.878,Gain of Relative solvent accessibility (Pr = 0.30 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.02); Gain of Disulfide linkage at C53 (Pr = 0.25 | P = 4.9e-03); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.13 | P = 5.8e-03), PS00407,-
GJB2_HUMAN,P58A,0.789,Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Altered Metal binding (Pr = 0.25 | P = 0.03); Gain of Disulfide linkage at C53 (Pr = 0.24 | P = 8.7e-03); Gain of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 6.9e-03), PS00407,-
GJB2_HUMAN,R75W,0.856,Altered Ordered interface (Pr = 0.27 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 9.5e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
GJB2_HUMAN,R75Q,0.727,Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
GJB2_HUMAN,E119K,0.440,-,-,-
GJB2_HUMAN,F115C,0.403,-,-,-
